G9143 HCPCS Level II code: Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)

G9143 is the HCPCS code for “Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)” in CMS’s October 2026 release, in effect from Oct 1, 2026.

Official description

G9143

Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)

Short description: Warfarin respon genetic test

HCPCS · United States

Medicare details

The indicators CMS publishes with G9143 in its October 2026 file. They describe Medicare’s handling, not another payer’s.

Medicare coverage
Carrier judgment
Medicare pricing
Physician fee schedule – Price established by carriers (e.g., not otherwise classified, individual determination, carrier discretion); Clinical lab fee schedule – Price subject to national limitation amount
Type of service
Medical care
BETOS category
Specialist - other
Lab certification
General immunology; Hematology
Added
Aug 3, 2009

Where G9143 sits

  1. 1G codesProcedures and professional services
  2. 2Active code G9143Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)

Source and release

Data release
HCPCS Level II · October 2026
Effective date
Oct 1, 2026
Publisher
CMS

This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.

Frequently asked questions

What does HCPCS code G9143 mean?

G9143 is the HCPCS code for “Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)” in CMS’s HCPCS Level II October 2026 release.

Does Medicare cover G9143?

CMS lists G9143’s Medicare coverage as “Carrier judgment” and its pricing as “Physician fee schedule – Price established by carriers (e.g., not otherwise classified, individual determination, carrier discretion); Clinical lab fee schedule – Price subject to national limitation amount”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.

Which HCPCS Level II release does this page use?

It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.

G9135Oncology; disease status; non-hodgkin's lymphoma, any cellular classification; stage iii, iv, not relapsed, not refractory (for use in a medicare-approved demonstration project)G9136Oncology; disease status; non-hodgkin's lymphoma, transformed from original cellular diagnosis to a second cellular classification (for use in a medicare-approved demonstration…G9137Oncology; disease status; non-hodgkin's lymphoma, any cellular classification; relapsed/refractory (for use in a medicare-approved demonstration project)G9138Oncology; disease status; non-hodgkin's lymphoma, any cellular classification; diagnostic evaluation, stage not determined, evaluation of possible relapse or non-response to…G9139Oncology; disease status; chronic myelogenous leukemia, limited to philadelphia chromosome positive and/or bcr-abl positive; extent of disease unknown, staging in progress, not…G9140Frontier extended stay clinic demonstration; for a patient stay in a clinic approved for the cms demonstration project; the following measures should be present: the stay must be…G9147Outpatient intravenous insulin treatment (oivit) either pulsatile or continuous, by any means, guided by the results of measurements for: respiratory quotient; and/or, urine urea…G9148National committee for quality assurance - level 1 medical homeG9149National committee for quality assurance - level 2 medical homeG9150National committee for quality assurance - level 3 medical homeG9151Mapcp demonstration - state provided servicesG9152Mapcp demonstration - community health teams